Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche’s MabThera Launch Triggers $5M Halozyme Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Roche’s MabThera Launch Triggers $5M Halozyme Milestone

Marks second product to use Halozyme's Enhanze technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Roche’s MabThera SC has launched in Europe, triggering a $5 million milestone payment to Halozyme Therapeutics under the companies’ license and collaboration agreement. In addition to Herceptin SC, MabThera SC is the second subcutaneous formulation of one of Roche’s oncology products to use Halozyme’s Enhanze (recombinant human hyaluronidase) technology.
 
MabThera SC is approved for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. This formulation could potentially save time for patients, physicians and health care providers.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics